Indeed, patients with luminal A/B or HER2 amplified breast cancer are likely to benefit from endocrine therapy or HER2 targeted therapies, respectively, while TNBC patients are commonly treated with chemotherapy and radiotherapy [10]. The gene discussed is ERBB2; the disease is breast carcinoma.